Hemagglutination inhibition of Cromer blood group antibodies with soluble recombinant decay-accelerating factor

Transfusion

Volumn 38, Issue 4, 1998, Pages 332-336

  Daniels, G L ^a   Green, C A ^b   Powell, R M ^c   Ward, T ^c  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b Bristol Inst for Transfus Sciences   (United Kingdom)

^c UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIBODY; BLOOD GROUP ANTIGEN; DECAY ACCELERATING FACTOR; MONOCLONAL ANTIBODY; RECOMBINANT DECAY ACCELERATING FACTOR; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; ARTICLE; ENDOMYCETALES; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN TISSUE; NONHUMAN; NUCLEOTIDE SEQUENCE;

EID: 0031946976     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1998.38498257370.x     Document Type: Article

References (19)

1. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989;7:35-58.
2. Coyne KE, Hall SE, Thompson ES, et al. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol 1992;49:2906-13.
3. Brodbeck WG, Liu D, Sperry J, et al. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J Immunol 1996;156:2528-33.
4. Kuttner-Kondo L, Medof ME, Brodbeck W, Shoham M. Molecular modeling and mechanism of action of human decay-accelerating factor. Protein Eng 1996;9:1143-9.
5. Telen MJ, Hall SE, Green AM, et al. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med 1988;167:3-8.
6. Daniels G. Human blood groups. Oxford: Blackwell 1995:567-81.
7. a epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology. Blood 1994;84:3205-11.
8. b on decay-accelerating factor (letter). Transfusion 1995;35:278.
9. Lublin DM, Kompelli S, Reid ME. Molecular basis of Cromer blood group antigens (absract). Transfusion 1997;37(Suppl):102S.
10. Lublin DM, Thompson ES, Green AM, et al Dr (a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants. J Clin Invest 1991;87:1945-52.
11. a (letter). Transfusion 1988;28:289-90.
12. a by human platelet concentrates (letter). Transfusion 1991;31:286.
13. a (letter). Transfusion 1981;21:579.
14. a: a high-frequency blood group antigen. Transfusion 1983;23:124-7.
15. Walthers L, Salem M, Tessel J, et al. The Inab phenotype: another example found (abstract). Transfusion 1983;23:423.
16. Powell RM, Ward T, Evans DJ, Almond JW. Interaction between echovirus 7 and its receptor, decay-accelerating factor (CD55): evidence for a secondary cellular factor in A-particle formation. J. Virol 1997;71:9306-12.
17. Ward T, Pipkin PA, Clarkson NA, et al. Decay-accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno-focal cloning method. EMBO J 1994;13:5070-4
18. Moulds JM, Rowe KE. Neutralization of Knops system antibodies using soluble complement receptor 1. Transfusion 1996;36:517-20.
19. Petty AC, Daniels GL, Anstee DJ, Tippett P. Use of the MAIEA technique to confirm the relationship between the Cromer antigens and decay-accelerating factor and to assign provisionally antigens to the short-consensus repeats. Vox Sang 1993;65:309-15.